Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24045407 | 0.82 | HTR1A (0.51) | LMNAMEN1KMT2AHTTSLC6A4 | |
| SCHEMBL17937298 | 0.80 | SLC6A4 (0.40) | SLC6A4SLC6A3HTR1A | |
| SCHEMBL7357631 | 0.79 | HTR1A (0.62) | SLC6A4SLC6A3HTR1A | |
| SCHEMBL7998697 | 0.78 | HTR1A (0.52) | SMN1; SMN2MEN1KMT2AHTTSLC6A4 | |
| SCHEMBL16596083 | 0.77 | GRIN2B (0.45) | MEN1KMT2ASLC6A4SLC6A3 | |
| SCHEMBL21122987 | 0.77 | GRIN2B (0.45) | MEN1KMT2ASLC6A4SLC6A3 | |
| SCHEMBL7985198 | 0.76 | MAPT (0.50) | ALDH1A1LMNAMEN1KMT2AHTR1A | |
| SCHEMBL18069816 | 0.74 | GRIN2B (0.45) | MEN1KMT2ASLC6A4SLC6A3 | |
| SCHEMBL7983037 | 0.73 | GRIN2B (0.61) | SLC6A4SLC6A3HTR1A | |
| SCHEMBL20202580 | 0.73 | LMNA (0.45) | ALDH1A1SMN1; SMN2LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2594564-B1 | 2-acylaminopropanol-type glucosylceramide synthase inhibitors | GENZYME CORP (US) | 2016-09-28 | — | — | EP | disclosed |
| EP-2594562-B1 | 2-acylaminopropanol-type glucosylceramide synthase inhibitors | GENZYME CORP (US) | 2016-07-20 | — | — | EP | disclosed |
| WO-2010014554-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITION FOR THE TREATMENT OF COLLAPSING GLOMERULOPATHY AND OTHER GLOMERULAR DISEASE | GENZYME CORPORATION (US) | 2010-02-04 | — | — | WO | disclosed |
| WO-2009117150-A2 | METHOD OF TREATING LUPUS WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2008150486-A2 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |